News

Filter

Current filters:

RepligenNeurological

Repligen in $70 million deal with Pfizer for SMA program

04-01-2013

USA-based Repligen (Nasdaq: RGEN) saw its share jump 5.6% to $6.63, after the company revealed it has…

BiotechnologyLicensingNeurologicalPfizerPharmaceuticalRare diseasesRepligenRG3039

Repligen plunges as bipolar drug flops in Ph IIb trial

08-03-2011

USA-based Repligen (Nasdaq: RGEN) saw its shares plummet 29.1% to $3.48 by mid-afternoon trading yesterday,…

NeurologicalPharmaceuticalRepligenResearch

Back to top